drugset

drugset / Trial / NCT03220646

Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

NCT03220646 ↗

Phase 2 Active not recruiting 64 enrolled Memorial Sloan Kettering Cancer Center Eli Lilly and Company · collab

Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.

Timeline

Start: 2017-07-13
Primary completion: 2027-07
Completion: 2027-07

Publications

Kaley TJ, Grommes C, Coffee E, Young RJ, Morrison T, Daher A, Schaff LR, Deng Y, Nandakumar S, Diamond EL, DeAngelis LM, Panageas KS, Gavrilovic I, Lin A, Pentsova E, Stone J, Santomasso BD, Piotrowski AF, Nair S, Schultz N, Reiner AS, Mellinghoff IK. Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma. Neuro Oncol. 2025 Dec 1;27(12):3189-3199. doi: 10.1093/neuonc/noaf184.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abemaciclib	Small molecule	200 mg	Oral

Indications